PEAR.Q Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17
Pear Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
PEAR.Q Community Narratives
There are no narratives available yet.
Pear Therapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2022
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.53
- Gross Margin
- 41.75%
- Net Profit Margin
- -594.70%
- Debt/Equity Ratio
- 89.7%
Pear Therapeutics, Inc. Competitors
Snowflake Analysis
About PEAR.Q
- Founded
- 2013
- Employees
- 200
- CEO
- WebsiteView website
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology. Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.4%
- 3 Months: 7.8%
- 1 Year: 17.8%
- Year to Date: 14.7%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 3.7%. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›